These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27528644)

  • 1. The US Food and Drug Administration and Cardiovascular Medicine: Reflections and Observations.
    Califf RM
    Circulation; 2016 Aug; 134(7):501-3. PubMed ID: 27528644
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in cardiovascular pharmacology.
    Hayes AH
    JAMA; 1982 Aug; 248(5):537-43. PubMed ID: 7097893
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials.
    Whyte J; Woodcock J; Wang J
    JAMA Intern Med; 2017 May; 177(5):724-727. PubMed ID: 28288256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?
    Meyer RJ
    Clin Pharmacol Ther; 2017 Aug; 102(2):186-188. PubMed ID: 28636269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 6. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
    Roden DM; Temple R
    Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
    Vaduganathan M; Sathiyakumar V; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2018 Dec; 72(25):3370-3372. PubMed ID: 30409566
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
    Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings of the nineteenth annual symposium: advances in cardiovascular pharmacology: protocol design and methodology. the U.S. Regulatory Process. May 3, 4, 5, 2000, Washington, D.C.
    Am J Ther; 2001; 8(3):187-219. PubMed ID: 11344386
    [No Abstract]   [Full Text] [Related]  

  • 11. Between a rock and a hard place.
    Demaria AN
    J Am Coll Cardiol; 2010 Nov; 56(21):1761-2. PubMed ID: 21070930
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganging up on the FDA.
    Stone PH
    Natl J (Wash); 1995 Feb; 27(7):410-4. PubMed ID: 10140321
    [No Abstract]   [Full Text] [Related]  

  • 14. An analysis of FDA-approved drugs for cardiovascular diseases.
    Kinch MS; Surovtseva Y; Hoyer D
    Drug Discov Today; 2016 Jan; 21(1):1-4. PubMed ID: 25218930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic heart medications.
    Harv Heart Lett; 2012 Nov; 23(3):8. PubMed ID: 23409308
    [No Abstract]   [Full Text] [Related]  

  • 16. Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020.
    Chen S; Li J
    JAMA Netw Open; 2021 Mar; 4(3):e212640. PubMed ID: 33755163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Policy and Cardiovascular Medicine.
    Ross JS; Kesselheim AS
    Circulation; 2015 Sep; 132(12):1136-45. PubMed ID: 26391294
    [No Abstract]   [Full Text] [Related]  

  • 18. In need of rehab.
    Nature; 2005 Oct; 437(7060):789-90. PubMed ID: 16208322
    [No Abstract]   [Full Text] [Related]  

  • 19. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
    Psaty BM; Weiss NS; Furberg CD; Koepsell TD; Siscovick DS; Rosendaal FR; Smith NL; Heckbert SR; Kaplan RC; Lin D; Fleming TR; Wagner EH
    JAMA; 1999 Aug; 282(8):786-90. PubMed ID: 10463718
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA efforts shift to 'urgent' issues.
    Kennedy D
    US Med; 1978 Jan; 14(2):13, 16. PubMed ID: 10306475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.